PRMT1 inhibitors (Cancer Therapeutics CRC)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePRMT1 inhibitors (Cancer Therapeutics CRC)
Drug Alias Nameprotein arginine N-methyltransferase-1 inhibitors (Cancer Therapeutics CRC)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein arginine N-methyltransferase 1 inhibitors
TargetsProtein arginine N-methyltransferase 1
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Therapeutics CRC Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCancer Therapeutics CRC Pty Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A